Eli Lilly and Company $LLY Shares Sold by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.4% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 15,971 shares of the company’s stock after selling 1,097 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Eli Lilly and Company were worth $12,450,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in LLY. Pioneer Trust Bank N A OR increased its position in Eli Lilly and Company by 5.3% in the 2nd quarter. Pioneer Trust Bank N A OR now owns 11,134 shares of the company’s stock valued at $8,679,000 after acquiring an additional 565 shares during the period. Advyzon Investment Management LLC boosted its position in Eli Lilly and Company by 68.7% during the 2nd quarter. Advyzon Investment Management LLC now owns 2,050 shares of the company’s stock worth $1,598,000 after acquiring an additional 835 shares during the period. VeraBank N.A. grew its stake in shares of Eli Lilly and Company by 5.1% in the second quarter. VeraBank N.A. now owns 3,089 shares of the company’s stock worth $2,408,000 after purchasing an additional 150 shares in the last quarter. Davidson Capital Management Inc. increased its holdings in shares of Eli Lilly and Company by 2.5% during the second quarter. Davidson Capital Management Inc. now owns 4,025 shares of the company’s stock valued at $3,138,000 after purchasing an additional 100 shares during the period. Finally, Cascade Financial Partners LLC increased its holdings in shares of Eli Lilly and Company by 0.5% during the second quarter. Cascade Financial Partners LLC now owns 236,056 shares of the company’s stock valued at $184,013,000 after purchasing an additional 1,070 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, November 3rd. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Guggenheim reissued a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 16th. Finally, Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $981.89.

Eli Lilly and Company Stock Up 2.2%

NYSE LLY opened at $987.48 on Wednesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $999.95. The company has a market capitalization of $933.55 billion, a P/E ratio of 64.54, a PEG ratio of 1.21 and a beta of 0.43. The company’s 50 day simple moving average is $809.69 and its 200 day simple moving average is $776.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period last year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.